EDIT

News Editas Medicine stock dips on proposed equity offering

7d ago

SEC filing EDIT Presents EDIT-401 Preclinical Data Showing ~90% Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates, Plans CTN Submission by Mid-2026

7d ago

News Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

14d ago

News The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts

14d ago

SEC filing EDIT Reports $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash, $123.6M Cash,

28d ago

News Editas Medicine GAAP EPS of -$0.06 beats by $0.20, revenue of $24.74M beats by $15.97M

85d ago

SEC filing EDIT Reports $146.6M Cash, $5.6M Q4 Net Loss, Launches IND/CTA for EDIT-401, 90% LDL-C Reduction Preclinical

85d ago

Insider trade Sale by Gilmore Neil O'Neill (CEO)

89d ago

Insider trade Sale by Linda Burkly (EVP, CHIEF SCIENTIFIC OFFICER)

89d ago

Insider trade Sale by Amy Parison (SVP, Chief Financial Officer)

89d ago

Scanner Unusual volume (2.2x average)

117d ago